Novartis Debuts Rapidly Manufactured Autologous CAR-Ts
Executive Summary
The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.
You may also be interested in...
Gilead's Kite To Buy Tmunity, Enhancing CAR-T Pipeline And Manufacturing
Kite CEO Christie Shaw said Tmunity brings three advantages: armored CAR-Ts, manufacturing technology and an ongoing research deal with the University of Pennsylvania.
Novartis’s John Tsai On The Four Philosophies Driving R&D
Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets.
ASH Preview: Three Areas To Watch In Hematology-Oncology
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.